Veradermics, Incorporated

NYSE: MANE · Healthcare · Biotechnology

PublicHQ New Haven, CT · New HavenCIK 0001827635Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 65DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$70.0M

Employees

as of 2026-08-01

Market cap

$4.4B

as of 2026-08-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$70.0M-$70.0M2025

Operating income-$72.3M-$72.3M2025

Total assets$152.6M$152.6M2025

Liabilities$9.2M$9.2M2025

Equity-$121.0M-$121.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Veradermics, Incorporated’s financial profile?

Veradermics, Incorporated earned -$70.0M in FY2025 net income.

Peers · Healthcare

Dyne Therapeutics, Inc.——Edgewise Therapeutics, Inc.——Celcuity Inc.——Enliven Therapeutics, Inc.——Legend Biotech Corporation——Galera Therapeutics, Inc.——

Neighbors

New Haven →

Trevi Therapeutics, Inc.——Biohaven Ltd.——Arvinas, Inc.$262.6M61C Rallybio Corporation$858.0k47D Precipio, Inc.$24.2M69B BioXcel Therapeutics, Inc.$642.0k27D

Key facts

CEOReid Waldman

SectorHealthcare

IndustryBiotechnology

HeadquartersNew Haven, CT

ExchangeNYSE: MANE

Employees21

IPO date2026-02-04

Latest filings

10-Q2026-08-11 8-K2026-08-11 8-K2026-07-15 10-Q2026-05-12 8-K2026-05-12 8-K2026-05-01 8-K2026-04-27 8-K2026-04-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.